Related Experiment Video

Updated: Mar 6, 2026

Author Spotlight: Purifying High-Quality Tubulin to Study Protein Dynamics and Therapeutic Applications
06:30

Author Spotlight: Purifying High-Quality Tubulin to Study Protein Dynamics and Therapeutic Applications

Published on: October 11, 2024

2.3K

Tubulin polymerization inhibitors in early clinical studies as cancer therapeutics

Ahmed Kamal1, Rahaman Shaik2, Prasanna Anjaneyulu Yakkalaa2

  • 1Department of Chemistry, Osmania University, Hyderabad, India.

Expert Opinion on Investigational Drugs
|March 4, 2026
PubMed
Abstract

Insights

Tubulin polymerization inhibitors (TPIs) are crucial in cancer therapy. This review examines early clinical TPIs, highlighting their evolution into precision medicines for targeted cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Microtubules are vital for cancer cell division and function.
  • Inhibiting tubulin polymerization is a key anticancer drug development strategy.
  • Tubulin polymerization inhibitors (TPIs) target these essential cellular processes.

Purpose of the Study:

  • To review TPIs in early clinical stages.
  • To evaluate their classification, preclinical and clinical data.
  • To explore challenges and future directions in TPI development.

Main Methods:

  • Literature search from January 2018 to January 2026.
  • Databases used: PubMed, Scopus, Embase, Web of Science, ClinicalTrials.gov, Google Scholar.
  • Keywords: tubulin polymerization inhibitors, clinical trials.

Main Results:

  • TPIs are categorized by binding sites: colchicine, vinca alkaloid, taxane.
  • Preclinical studies show antiproliferative activity and synergy with other treatments.
  • Clinical trials assess efficacy, toxicity, and patient selection via biomarkers.

Conclusions:

  • TPIs are transitioning to precision medicines targeting cancer-specific molecular differences.
  • Biomarkers like βIII-tubulin aid personalized therapy.
  • Nanotechnology and immunotherapy integration promise enhanced efficacy and reduced toxicity.
Keywords:
Tubulin polymerizationcancerclinical trialsresistancetubulin inhibitors

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

8.0K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.8K
Microtubule Formation01:23

Microtubule Formation

Microtubules are dynamic structures that undergo continuous assembly and disassembly. They originate from specialized multi-protein complexes known as microtubule organizing centers or MTOCs. Within the MTOC, the point of origin of the microtubule is known as the minus end, while the end radiating outward is the plus end. Microtubules serve two primary functions — the organization of spindle complexes to separate sister chromatids during mitotic or meiotic cell division and the formation...
8.0K